$300MSeries A, 15 April 2026
Launched with five programs licensed from Bristol Myers Squibb.
- Amount
- $300M
- Stage
- Series A
- Announced
- 15 April 2026
- Lead
- Bain Capital Life Sciences
- Use of funds
- Launched with five programs licensed from Bristol Myers Squibb.
- Checked
- Amount and date matched across 2 press sources
- Sources
- Beeline Medicines emerges with $300M Series A pharmaphorum.com
Beeline Medicines emerges with $300M Series A techstartups.com